Standard: Statement of policy intent: relaunch of the Innovative Licensing and Access Pathway

⌂Back To Homepage Subscribe To RSS Feed

Medicines Healthcare Products Regulatory Agency

November 6

09:00 2024

Print This Article Share it With Friends

Created by Medicines Healthcare Products Regulatory Agency 0 comments

class="gem-c-govspeak govuk-govspeak gem-c-govspeak--direction-ltr govuk-!-margin-bottom-0">

The Innovative Licensing and Access Pathway (ILAP) aims to get the most transformative new medicines to patients in the National Health Service (NHS) more quickly.

It is the only end-to-end access pathway where the developer can work collaboratively with the UKs national health system, the regulator, and health technology assessment bodies from the early stages of clinical development.

Published 6 November 2024

Help us improve GOV.UK

To help us improve GOV.UK, wed like to know more about your visit today. Please fill in this survey (opens in a new tab).



View the original news story

Scroll Back To Top 📄More Articles

Comments

Scroll Back To Top ✎Write Comment

We don't have any comments for this article yet. Why not join in and start a discussion.

Your name:	Your email:
Comments:
Post my comment

GovWire